Download MendeleyPyrazolone based TGFbetaR1 kinase inhibitors.
Guckian, K., Carter, M.B., Lin, E.Y., Choi, M., Sun, L., Boriack-Sjodin, P.A., Chuaqui, C., Lane, B., Cheung, K., Ling, L., Lee, W.C.(2010) Bioorg Med Chem Lett 20: 326-329
- PubMed: 19914068
- DOI: https://doi.org/10.1016/j.bmcl.2009.10.108
- Primary Citation of Related Structures:
3KCF - PubMed Abstract:
Interruption of TGFbeta signaling through inhibition of the TGFbetaR1 kinase domain may prove to have beneficial effect in both fibrotic and oncological diseases. Herein we describe the SAR of a novel series of TGFbetaR1 kinase inhibitors containing a pyrazolone core. Most TGFbetaR1 kinase inhibitors described to date contain a core five-membered ring bearing N as H-bond acceptor. Described herein is a novel strategy to replace the core structure with pyrazolone ring, in which the carbonyl group is designed as an H-bond acceptor to interact with catalytic Lys 232.
Organizational Affiliation:
Biogen Idec Inc., 14 Cambridge Center, Cambridge, MA 02142, USA. kevin.guckian@biogenidec.com
